Oncogene ( 
It came as a considerable surprise to virologists in 1962 when John Trentin and his colleagues reported that a human adenovirus was oncogenic. At Baylor University (Houston, Texas) they had been inoculating newborn hamsters with human adenoviruses and found that adenovirus serotype 12 (Ad12) induced tumours in a high proportion of the animals injected. Other Ad serotypes (Ads) were found to be non-tumorigenic (this included Ad2, which with its closely related non-oncogenic serotype Ad5, have been the most extensively studied Ads; referred to in this review as Ad2/5). This important observation was initially greeted with some scepticism (see Gross, 1966) . However, Ad12 oncogenesis was rapidly con®rmed by others (Huebner et al., 1962) and lead to more extensive in vivo and in vitro studies on the capacity of human Ads to disrupt normal cell growth control. It is not possible to review all of the literature on this subject here but there are a number of reviews that cover this subject (Gross, 1966; Gallimore et al., 1984; Williams et al., 1995) . From the in vivo studies in the 1960's it soon became clear that there were indeed tumorigenic (Huebner et al., 1962; Trentin et al., 1962 , Girardi et al., 1964 Pereira et al., 1965) and nontumorigenic adenoviruses (Trentin et al., , 1968 . As well as Ad serotype, adenovirus induced tumorigenicity was found to be dependent on virus dose , host genetic constitution (Yabe et al., 1964 , Yohn et al., 1965 Allison et al., 1967) , age at inoculation and the host's immune status (Yohn et al., 1965; Allison et al., 1967) . Around this time tissue culture studies revealed that rodent cells were susceptible to adenovirus transformation and that both tumorigenic (McBride and Wiener, 1964) and non-tumorigenic Ads (Freeman et al., 1967) induced morphological transformation from which immortal cell lines could be easily derived. Studies on immortal rodent cell lines showed that the cells transformed by non-oncogenic viruses could be tumorigenic, but only in immunocompromised hosts (Gallimore, 1972 , Gallimore et al., 1977 .
The next logical step in adenovirus research was to identify the virus genes responsible for transformation and/or tumorigenicity. Unlike today, no restriction enzymes were readily available and there was no Southern blotting technique (Southern, 1975) . Fujinaga and Green used membrane hybridization to show that adenovirus sequences were indeed retained and expressed in Ad transformed cells (Fujinaga and Green, 1970) . This was followed by the ®rst attempt to utilize restriction endonucleases and C o t analysis (Pettersson and Sambrook, 1973) to map the viral sequences in an Ad2 transformed line, Ad2/8617. In the following year, a more extensive study found that a minimal region of the virus genome representing the left hand 14% was common to nine independently isolated Ad2 transformed rat embryo cell lines . This strongly suggested, but did not prove, that the Ad transforming gene resided in this region of the Ad genome. With the development of the calcium phosphate DNA transfection technique (Graham and van der Eb, 1973) and the use of de®ned Ad DNA fragments, it was convincingly shown that this region was responsible for the induction of transformation (Graham et al., 1974a,b) . RNA mapping was carried out Flint et al., 1975) which de®ned the early region transcripts (reviewed by Shenk and Flint, 1991; Shenk, 1996) and later designated E1 (E1A+E1B) E2, E3 and E4 (Kitchingman et al., 1977) . Viral RNA selected on speci®c Ad DNA fragments was then used in transcription/translation assays to identify the proteins expressed from these regions and their molecular weights (Lewis et al., 1976; Harter and Lewis, 1978; Halbert et al., 1979) . The E1A proteins were found to have a molecular weight range from approximately 28 to 58 kDa.
The next major step in our understanding of E1A was facilitated by the isolation of the now famous 293 cells, human embryo kidney cells transformed by Ad5 DNA (Graham et al., 1977) . These cells expressed the Ad5 E1 transforming proteins that provided a permissive environment for replication-and transformation-defective E1 region mutants (Frost and Williams, 1978; Graham et al., 1978) . Similar cell lines were developed for the isolation of Ad12 mutants (Byrd et al., 1982) . The E1 regions of Ad2/5 and Ad12 were subjected to extensive genetic analysis (Jones and Shenk, 1978, 1979; van der Eb et al., 1979; Bos et al., 1983; Gallimore et al., 1985; Breiding et al., 1988; Byrd et al., 1988b) . These Ad E1 mutant viruses along with viral DNA transfection experiments revealed that the E1A region alone could only induce partial transformation or unstable transformation and that for full transformation and oncogenicity, E1A had to be complemented by functions provided by the E1B region (Houweling et al., 1980; Bernards et al., 1983a; Ruley, 1983; van den Elsen et al., 1983a,b; Gallimore et al., 1985; Barker and Berk, 1987; Byrd et al., 1988a,b) .
It was reported, around this time, that Ad12 E1A but not the non-tumorigenic Ad2/5 E1A, downregulated MHC class I in rat transformed cells, thereby interfering with viral antigen presentation to the host's cell mediated immunity (Bernards et al., 1983b; Schrier et al., 1983) . Ad12 but not Ad2 transformed cells were also shown to be resistant to NK cell killing (Raska and Gallimore, 1982) . The sensitivity of Ad2/5 transformed rodent cells to NK cell killing was shown to be due to E1A (Cook et al., 1987; Krantz et al., 1996) . E1A has also been shown to be a tumour speci®c transplantation antigen (Gallimore and Williams, 1982; Urbanelli et al., 1989) . More recent studies have shown that Ad12 E1A can interfere with additional aspects of the antigen presentation pathway in Ad12 transformed cells (Rotem-Yehudar et al., 1994; Prott and Blair, 1997; recent review by Philpott and Blair, 2001 ). These studies provide evidence for the oncogenic nature of Ad12 E1A but are not the complete explanation.
The sequencing of Ad E1A and E1B regions (van Ormondt et al., 1978; Fujinaga et al., 1979; Perricaudet et al., 1979; van Ormondt et al., 1980; Dijkema et al., 1982) , along with the characterization of the E1A mRNAs in infected and transformed cells (Berk and Sharp, 1978; Kimelman et al., 1985; Perricaudet et al., 1979; Sugisaki et al., 1980) lead to the identi®cation of E1A conserved regions (CR), CR1, CR2 and CR3 (Kimelman, 1986) . The predominant Ad E1A mRNAs early in viral infection and in transformed cells are the 13S and 12S E1A mRNAs. These only dier through the utilization of dierent splice donor sites (see Boulanger and Blair, 1991; Shenk and Flint, 1991) . 13S mRNA encodes a 289R protein in the case of Ad2/5 and 266R for Ad12; whilst Ad2/5 and Ad12 12S mRNAs encode polypeptides of 243R and 235R respectively. The additional coding capacity in the 13S mRNA encompasses the CR3 region of the E1A proteins.
These conserved regions along with arginine at position 2, the PXDLS motif and a short run of basic residues at the C-terminus are regions common to all Ad E1As. The oncogenic serotypes have an additional alanine-rich region between CR2 and CR3 that has been shown to be important for tumour induction (Jelinek et al., 1994; Telling and Williams, 1994; Williams et al., 1995) . Many of the biological properties of E1A have been mapped to these conserved regions (Bayley and Mymryk, 1994; Moran, 1994; Williams et al., 1995; Grand, 2001 ).
The development of E1A speci®c monoclonal antibodies (Harlow et al., 1985) with co-immunoprecipitation, identi®ed a number of cellular proteins associated with E1A (for an up to date summary of the E1A binding proteins and their binding sites on E1A see Figure 1 ). The ®rst of these to be identi®ed was the recently cloned retinoblastoma tumour suppressor protein, Rb1 (Whyte et al., 1988 (Whyte et al., , 1989 . This seminal observation led to the surprising ®nding that the oncoproteins from unrelated DNA tumour viruses targeted Rb1 (DeCaprio et al., 1988; Dyson et al., 1989) and was a de®ning moment in the ®eld of cancer biology. Additional E1A binding proteins have now been identi®ed as tumour suppressor proteins like p300 (Jacobson and Pillus, 1999; Gayther et al., 2000) and CBP (Lavau et al., 2000) and this may not be the ®nal tally.
Although E1A is an extensively studied molecule, so far, it has eluded attempts to de®ne its structure (Grand, 2001 ). There are a number of reasons for this, over expression of E1A in eukaryote cells leads to apoptosis (White, 1998) , the majority of E1A expressed in E. coli is insoluble or it may have only limited structure until it is complexed with partner proteins (Bayley and Mymryk, 1994) . Using peptide mimicry and NMR spectroscopy we have resolved structures for the N-terminal portion of CR3, the TBP binding site (Molloy et al., 1999) , this was found to form an a helix whilst the CtBP binding site (including the PXDLS motif, Shaeper et al., 1995) formed a series of b turns (Molloy et al., 1998) . Bioinformatic predictions suggest that E1A also has secondary structure at the Nterminus over the region where a number of cellular proteins bind (Molloy, personal communication) . This includes an a-helix extending from residues 13 to 29 and three regions of antiparallel b strand between residues 37 to 77. Could it be that the limited regions with apparent structure form high anity binding sites and the binding of cellular/viral protein partners provides additional structural constraints to E1A necessary for the docking of other proteins with lower anity?
Recently, adenovirus E1 mutant viruses have been utilized as potential therapeutic agents. One area of active research is in the use of adenoviruses as anticancer agents. The Ad5 E1B mutant dl1520 (Barker and Berk, 1987) , a 58K null virus, was developed by ONYX Pharmaceuticals as ONYX 015 and has been studied in a number of phase I and phase II clinical trials (Kirn, 2000) . Ad5 dl1520 eciently expresses E1A (Barker and Berk, 1987) and in one of the most recent trials it has been shown to be therapeutic in combination with an anticancer drug cisplatin in patients with recurrent head and neck carcinomas (Khuri et al., 2000) . In this instance, E1A is probably acting as a chemosensitizing agent. In a more recent study, it has been shown that ONYX 015 can be safely administered systemically by the intravenous route and thereby extending potential anticancer activity to disseminated disease (Nemunaitis et al., 2001) . Other approaches have been to develop adenoviruses with mutated E1A that will only replicate in cells with defects in the Rb pathway (Fueyo et al., 2000) or to utilize the ability of E1A to down-regulate the ErbB2 growth factor receptor (e.g. breast carcinomas) where this is a crucial feature of tumour cell maintenance (Yu and Hung, 2000) .
Much of what we have learned about E1A in recent years has been associated with transcriptional regulation. The next section of this review focuses on our interpretation of the current status of this ®eld and some of our views on additional E1A functions.
Recent insights into E1A function

E1A as a transcriptional regulator
In the Ad virion the viral genome is packaged with the basic viral core proteins, V and VII, in a`nucleosome'-like structure (Russell et al., 1971; Brown et al., 1975) , whereas during very early Ad infection viral DNA complexes with core protein VII predominate (Chatterjee et al., 1986) . It has been suggested that during early Ad infection viral DNA dissociates from core proteins and that naked Ad DNA rapidly becomes chromatinized' by host cell histones (Dery et al., 1985) . Transcription of viral genes has been proposed to occur from both core templates (Matsumoto et al., 1995) and cellular histone templates (Dery et al., 1985) , although how this relates to primary infection in the natural host is unknown. E1A plays a signi®cant role in regulating the temporal transcription pattern of Ad genes necessary for viral replication, and also reprogramming host cell transcription to induce S phase (Shenk, 1996) . The ability of E1A to regulate both host cell, and viral transcription, resides in its capacity to interact with a number of host cell proteins that function as transcription factors (e.g. ATF-2, YY1), co-activators (CBP/p300), co-repressors (CtBP), nucleosomal remodelling factors (SWI/SNF-mating type switching and sucrose non-fermenting) or comprise the general transcription machinery (TBP, TAFs) itself (Bayley and Mymryk, 1994; Mymryk and Smith, 1997) .
Generally, Ad viral gene transactivation is mediated through the CR3 region of the 13S-encoded E1A protein, the region of the molecule that binds numerous transcription factors (Figure 1 ), and the general transcriptional machinery (Jones, 1995) . The role of CR3 in stimulating viral gene transcription is beyond the scope of this current review, though recent evidence suggests that the transactivating capacity of CR1 CR2 CR3 Figure 1 Linear representation of Ad2/5 13S E1A, indicating regions of conservation between serotypes, known structural motifs (zinc ®nger) and structural features (acetylation site and NLS-nuclear localization signal). The binding sites for known E1A-interacting proteins are also shown. Also represented are the known functional domains of E1A that participate in transformation, transcriptional activation/repression and suppression of dierentiation. Finally, E1A shares limited homology with a small number of cellular proteins that often encompasses a binding site for a known interacting protein (e.g. RIZ, Buyse et al., 1995) ± these are also depicted. See text for explanation CR3 correlates positively with the ability of E1A to bind hSUR2 (Boyer et al., 1999) , a component of transcriptional mediator. However, there are instances where reports have highlighted other regions of E1A being involved in viral gene activation (Jones, 1995; and see later) . It is possible that 12S-encoded E1A (243R, Ad5) and 13S-encoded E1A (289R, Ad5) perform separate general functions; 243R repressing transcription, 289R stimulating transcription. In the context of transcriptional reporter assays, repression is exclusively associated with the 243R product, whereas transcriptional activation is mediated by both 243R and 289R (Jones, 1995) . There is also evidence to suggest that 243R and 289R are temporally regulated during infection. The 289R molecule is a short-lived species (Spindler and Berk, 1984) , whereas 243R expression persists throughout viral infection. Whether this speci®cally relates to a period of transcriptional activation followed by a period of transcriptional repression is currently unknown. Moreover, there is evidence from simple reporter assays to suggest that 243R and 289R can dierentially regulate the same promoter (e.g. GPH-a promoter; Pestell et al., 1996) . Thus, 289R and 243R could temporally regulate a subset of promoters during viral infection, to initially stimulate transcription and subsequently repress transcription. However, it must be borne in mind that the functional consequence of E1A binding to a partner protein, might depend on the species (243R or 289R) to which it binds, and obviously the complement of other binding proteins present in the complex.
Chromatin remodelling
Remodelling of chromatin for activation or suppression of gene expression requires enzymic activities provided by histone-directed acetyltransferases (HATs), histone-directed deacetylases (HDACs), nucleosomal-remodelling factors such as the SWI/SNF family of proteins and nucleosomal-associated proteins (Cheung et al., 2000; Aalfs and Kingston, 2000) . E1A impinges on chromatin remodelling factors either directly or indirectly to regulate both cellular and viral gene transcription. The N-terminus through CR1 eects transcription through interaction with the HAT proteins, CBP/p300 (Eckner et al., 1994; Arany et al., 1995) , P/CAF (Yang et al., 1996) , and SWI/SNF family member, p400 (Fuchs et al., 2001) . CR1, CR2 and the C-terminus of the molecule interact with Rb (Whyte et al., 1988) and CtBP (Boyd et al., 1993) to modulate HDAC and SWI/SNF function. What is the signi®cance of E1A binding to these cellular factors in regulating cellular and viral gene transcription?
CBP/p300 and P/CAF acetyltransferases Some reports suggest that E1A inhibits HAT activity of p300 and P/CAF directed towards core histones and p53, such that E1A inhibits CBP/p300 co-activator function (Chakravarti et al., 1999; Hamamori et al., 1999) . It might be suspected that if E1A ablates CBP/ p300 function that it would achieve this by displacing proteins, such as P/CAF, TFIIB and RNA pol II from an E1A-binding site on CBP/p300, and/or sequestering CBP/p300 from active sites of transcription on chromatin. Interestingly, however, E1A itself has recently been identi®ed as a substrate for acetylation at Lys-239 (Ad5 12S product; Lys-285, 13S product), a residue proximal to the CtBP-binding site . Indeed, in one of the reports suggesting that E1A inhibits p300 HAT activity, it was evident from assays designed to investigate E1A eects on histoneand p53-directed acetylation that E1A was also a substrate for p300-mediated acetylation (Chakravarti et al., 1999) . Thus, the interpretation that E1A inhibits acetyltransferase activity in general might be an oversimpli®cation. A separate report has suggested that E1A stimulates intrinsic p300 HAT activity (Ait Si Ali et al., 1998) , such that E1A may actually utilize CBP/ p300 to stimulate transcription, rather than inhibit its function.
Perhaps crucially, recent reports suggest that functional HAT activity is required for some of E1As functions in vivo. For example, Ad12E1A-dependent transcriptional activation of the Ad12 E2 promoter is dependent upon the recruitment of CBP/p300 to E1A and to the E2 promoter (Fax et al., 2000a,b) . Moreover, recent data suggests that recruitment of CBP/p300 to E1A facilitates acetylation of Rb species found in complex with E1A (Chan et al., 2001) ; acetylation of Rb enhances binding to Hdm2. The ability to recruit CBP/p300 and Rb as core components of a functional complex may not be unique to E1A. The region spanning the N-terminus and CR1 (residues 1 ± 71, Ad12) de®nes an activation domain that is conserved at the C-terminus (residues 365 ± 435) of E2F-1 (Trouche and Kouzarides, 1996) . The consequences of CBP/p300 and Rb binding to these homologous activation domains are identical. CBP/ p300 stimulates both activation domains, whereas Rb represses them. As Rb and CBP/p300 apparently have opposing eects on E1A, it is unclear at present why E1A would recruit both proteins to the same complex. Potentially, recruitment of Hdm2 to acetylated Rb, might alter Rb activity. Alternatively, CBP/p300 and Rb might function dierently when recruited to a multicomponent complex.
The apparent ability of E1A to inhibit CBP/p300 function in some circumstances and yet utilize CBP/ p300 HAT activity in other instances, must be rationalized in the context of promoter targeting and E1A function during viral infection (Figure 2a) . It is plausible that E1A could re-direct CBP/p300 activity from a transcriptionally active cellular promoter, thus inhibiting activity, to an inactive viral or cellular promoter that the E1A-CBP/p300 complex subsequently activates. The ability of E1A to dierentially regulate CBP/p300 might also re¯ect the composition of the CBP/p300 complexes targeted, and the transcriptional status of CBP/p300. Thus, E1A might recruit binding proteins to form a large multi-component complex that, dependent on the core components, determines whether E1A stimulates, or represses, transcription. Obviously, multiple E1A-containing complexes might exist to aect speci®c targets.
p400-a SWI/SNF nucleosomal remodelling factor?
The SWI/SNF family of proteins can stimulate or repress transcription, dependent on the cellular context. This inherent ability resides in the capacity of SWI/ SNF proteins to remodel nucleosomal architecture in an ATP-dependent manner, facilitating either transcription factor association, or dissociation, with cognate promoters (reviewed by Sudarsanam and Winston, 2000) . It has been known for many years that the Nterminus of E1A interacts with a 400 kDa protein, p400 (Barbeau et al., 1994) . Until very recently, the function of the p400 protein was unknown. Cloning and characterization of the p400 protein has revealed however, that it is related to SWI2/SNF2 (Fuchs et al., 2001 ). E1A's interaction with p400 is essential for E1A-mediated transformation, as an E1A mutant that is defective for p400 binding is also defective in transformation assays. Akin to other SWI/SNF family members, p400 exists in macromolecular complexes, components including the Myc-associated factor TRRAP/PAF400, the DNA helicases TAP54a/b, actin-like proteins and the human homologue of the Drosophila Enhancer of polycomb protein (Fuchs et al., 2001) . Interestingly, E1A and Myc alter the subunit composition of p400 complexes, implying that physiological p400 complex formation contributes to transformation suppression (Fuchs et al., 2001) . Given the analogy with CBP/p300, it is conceivable that E1A could utilize SWI/SNF proteins to both stimulate and/ or repress transcription (Figure 2c,d) .
Rb-regulation of HDAC and SWI/SNF function
As depicted in Figure 1 , CR2 contributes towards binding the pocket-family of proteins, Rb, p107 and p130, displacing them from E2F family members and stimulating transcription from E2F-responsive promoters (Whyte et al., 1988; Li et al., 1993) . The LXCXE motif located in CR2 is crucial in mediating Rb binding. E1A may however, interfere with Rb functions independently of E2F binding. Rb functions as a transcriptional repressor, through recruitment of HDAC1 to promoter complexes (Brehm et al., 1998) . Rb achieves this through an LXCXE-like motif located at the C-terminus of HDAC1. Whether E1A disrupts Rb-HDAC complexes akin to HPV E7 (Brehm et al., 1998) in order to stimulate transcription is an intriguing possibility. However, it could be argued that E1A might, in a manner analogous to E1A utilization of CBP/p300, also recruit HDACs to repress transcription (Figure 2b ). More detailed analyses are required to determine the precise relationship between E1A, Rb and HDACs. The A/B pocket of Rb, p107 and p130 also binds to other proteins possessing the LXCXE motif. hBRM and BRG1, human homologues of the yeast SWI1/SNF2 transcriptional regulator, bind to Rb family members through LXCXE (Dunaief et al., 1994; Strober et al., 1996) . Functionally, Rb interaction with hBRM and BRG1 induces cell cycle arrest. This growth arresting ability is relieved by E1A, but not by E1A mutants incapable of binding Rb family members (Strober et al., 1996) . Thus not only does E1A impinge on HDACs through Rb, but also regulates SWI/SNF remodelling activities, by disrupting hBRM and BRG1 interaction with Rb.
E1A, through Rb, might also regulate DNA replication. Initiation of DNA replication in higher eukaryotes necessitates the loading of cellular DNA licencing factors to the origin of replication (Lei and Tye, 2001 ). The MCM (minichromosome maintenance) proteins are a family of licencing factors that are loaded onto the origin of replication as a heterohexameric entity to form part of the pre-replication complex. The MCM hexamer possesses intrinsic DNA helicase activity (Ishimi, 1997) that has been postulated to unwind DNA at active sites of replication. One of the MCM family members, MCM7, is targeted by Rb (Sterner et al., 1998) . Rb inhibits DNA replication through its association with MCM7. Whether E1A functions to disrupt Rb/MCM7 function to stimulate cellular DNA replication is an intriguing possibility.
The targeting by E1A of the chromatin remodelling factors could serve a number of purposes during infection: to repress host cell genes which control G1 arrest and dierentiation (e.g. Myo D); and to induce host cell genes required for cell cycle progression through activation of E2F (Dyson, 1998) . It now seems likely that E1A utilizes cellular HAT, HDAC and SWI/SNF activities to regulate the temporal expression of the viral genome. It must be borne in mind however, that a number of factors might determine the ®nal outcome. This would include the macromolecular composition of E1A complexes, the composition of HAT, HDAC and SWI/SNF complexes, the promoter being regulated and the host cell type. At this stage, it is unclear how all this relates to E1A function in the transformed cell. Here, integrated viral genomes will form part of the normal chromatin architecture of the cell, which may in¯uence the temporal regulation of E1A expression. It may be that the E1A species in transformed cells diers from E1A species in early infection. Is the major role of E1A in the transformed cell to facilitate continual cell cycle progression? If this is the case E1A will impinge on signaling pathways that regulate the phase after cytokinesis and prior to cell cycle re-entry. It might also be suspected that cell cycle status might in¯uence the ability of E1A to regulate cellular promoters in the transformed cell.
Exon 2 functions
CtBP Much of what has been discussed already is reliant on functions provided by exon 1 of E1A. However, exon 2 possesses distinct activities. Until recently, only one cellular protein was known to interact with exon 2 of E1A, C-terminal Binding Protein (CtBP) (Boyd et al., 1993; Schaeper et al., 1995) . The CtBP binding site is located towards the Cterminus of the protein and is de®ned by a PXDLS motif. The human CtBP family currently has three members, and homologous proteins identi®ed in Drosophila (Nibu et al., 1998; Poortinga et al., 1998) are key regulators of development, functioning as short-range transcriptional repressors. CtBP family members bind other transcriptional repressors, such as the homeodomain proteins, dEF1 and TGIF (Furusawa et al., 1999; Melhuish and Wotton, 2000) , through the PXDLS motif, presumably to form large multi-component repression complexes. CtBP can also interact directly with HDACs. One report suggests that E1A may alleviate transcriptional repression mediated by CtBP-HDAC complexes through inactivation of CtBP (Sundqvist et al., 1998) .
It is tempting to speculate that E1A similarly disrupts CtBP interaction with the homeodomain proteins and other PXDLS-containing proteins, to impinge on multiple transcriptional repression activities. Other cellular proteins containing the PXDLS motif also interact with CtBP. One of these, CtIP (Schaeper et al., 1998) , also binds to the BRCA1 tumour suppressor protein (Yu et al., 1998); CtIP-BRCA1 complex formation is implicated in BRCA1-mediated tumour suppression. Does E1A target CtBP to interfere with CtIP-BRCA1 function? As mentioned earlier, E1A is acetylated on Lys-239 (12S product). Mutation of this Lys residue to either Gln or Ala blocks CtBP binding in vitro and disrupts CtBP/E1A interaction in vivo . How E1A acetylation relates to E1A's ability to mediate viral replication and cellular transformation, awaits further investigation. Interestingly, Lys-239, comprises part of the E1A nuclear localization signal (NLS- Lyons et al., 1987) . Acetylation of E1A might therefore, also regulate E1A localization. Intriguingly, human importin-a is a substrate for CBP/p300 , implicating acetylation in nuclear import processes.
It has long been known that a substantial proportion of cellular E1A (up to 50% in some cells) is cytoplasmic (Rowe et al., 1983; Grand and Gallimore, 1984) . CtBP exists as cytoplasmic species. Indeed, recent evidence suggest that CtBP3/BARS participates in Golgi network assembly/disassembly (Weigert et al., 1999) , through an intrinsic lipid acyltransferase activity which generates phosphatidic acid from lyso-phosphatidic acid. All CtBP members isolated to date possess acyltransferase activity . It is possible that E1A targets CtBP directly to regulate Golgi network dynamics. Other cytoplasmic proteins have been identi®ed as targets for E1A. A recent report has indicated that E1A interacts with the cytoplasmic protein RIIa, a regulatory subunit of PKA (Fax et al., 2001) , although the exact site of interaction on E1A has yet to be determined. As a consequence of this interaction, RIIa is re-partitioned from the cytoplasm to the nucleus. It will be interesting to see if the E1A species that interacts with RIIa, is acetylated at Lys-239. Whether this ability of E1A is indicative of a more general role for E1A as a nuclear import factor is an intriguing possibility.
Dyrks (Yak-related kinases) Recent studies in Saccharomyces cerevisiae have identi®ed the C-terminus of E1A as a key regulator of pseudohyphal dierentiation (Zhang et al., 2001) . Two-hybrid studies identi®ed yak1p as a C-terminal E1A binding protein at a site distinct from CtBP. Interestingly, although yak1p induced Ras2p-dependent pseudohyphal dierentiation in S. cerevisiae, the ability of E1A to induce dierentiation did not correlate positively with its ability to bind yak1p. Genetic studies identi®ed the last ®ve amino acids of E1A (285 ± 289; Ad5 13S product) as crucial in mediating pseudohyphal dierentiation (Zhang et al., 2001) . Intriguingly, as the last ®ve residues of E1A encompass the NLS, this suggests that nuclear E1A is required to initiate pseudohyphal dierentiation. This study also identi®ed the mamma-lian orthologues of yak1p, Dyrk1A and Dyrk1B, as Cterminal E1A binding proteins. The consequence of E1A binding to Dyrk 1A and 1B was to stimulate intrinsic serine/threonine protein kinase activity in vitro (Zhang et al., 2001 ).
Modulation of transforming activity
Many studies have shown that either E1B or activated ras genes can co-operate with E1A in transformation (Ruley, 1983; Jochemsen et al., 1986; Byrd et al., 1988a; Douglas and Quinlan, 1995) . Interestingly, Ad5 E1A/ activated ras transformants were found to be highly malignant (Jochemsen et al., 1986) , suggesting that dierent signalling pathways are targeted by E1B and ras. Exon 2 of E1A plays a key role in E1A-mediated transformation. Exon 2 enhances E1A/E1B-mediated transformation (Douglas and Quinlan, 1995) . In contrast, exon 2 suppresses E1A/ras-mediated transformation, such that exon 2 deletion mutants enhance transformation by E1A/ras to give a`super-transformed' phenotype (Subramanian et al., 1989; Douglas et al., 1991) . The ability of exon 2 to repress transformation by ras resides, in part, in its ability to interact with CtBP since deletion mutants lacking the CtBP binding site enhance transformation (Boyd et al., 1993) . Interestingly, there is no apparent requirement for E1A to be targeted to the nucleus in its ability to co-operate with ras (E1A/E1B co-operation requires nuclear localization), since deletion of the NLS does not aect transformation eciency (Douglas and Quinlan, 1995) . How E1A binding to Dyrk1A and Dyrk1B relates to the ability of the C-terminus of E1A to co-operate with E1B or ras in transformation or whether these proteins are targets for E1A during infection are, as yet, important unanswered questions.
Additional functions of E1A
It is now apparent that E1A can regulate a number of important signalling pathways. These include stressresponse pathways (p53), pathways involved in regulating protein stability (proteasome/ubiquitylation) and immune response pathways (MHC1). As discussed in the previous section, E1A regulates many signalling pathways at the level of transcription. Indeed, the tumorigenic potential of adenovirus relates to its ability to evade immune surveillance, by down-regulating at the transcriptional level, MHC class 1 presentation. There are instances however, of E1A function that cannot be explained by transcriptional regulation alone. E1A interacts with the 26S proteasome to regulate protein stability and in concert with other arbiters of protein stability, stabilizes levels of p53. The following sections will detail how E1A impinges on these pathways by regulating both transcription and protein stability.
Stabilization of p53
The interplay between E1A and the p53-regulated pathways is complex (see Figure 3) . In transformed cells E1B proteins bind p53, and negate p53 transcriptional activity (Sarnow et al., 1982; Yew and Berk, 1992) ; however, in the early stages of viral infection E1A stabilizes p53. Indeed, transfection of E1A DNA into cells in culture, in the absence of other viral genes or co-operating cellular oncogenes similarly stabilizes p53 protein levels; E1A inducing p53-dependent apoptosis (Debbas and White, 1993; Lowe and Ruley, 1993; Grand et al., 1994; Sabbatini et al., 1995) . The ability of E1A to stabilize p53 resides in part in its ability to bind Rb and CBP/p300 (Chiou and White, 1997; Querido et al., 1997) . E1A binding to Rb, stabilizes p53 by stimulating the E2F-dependent transcription of p19 ARF (de Stanchina et al., 1998; p19 ARF is mouse and p14 ARF is the human orthologue), a protein that binds to, and inhibits, Hdm2 ubiquitin ligase activity directed towards p53 (Honda and Yasuda, 1999) . Similarly, E1A binding to CBP/p300, is thought to inhibit p53 degradation; CBP/p300 has also been implicated in regulating p53 degradation (Grossman et al., 1998) . E1A might also stabilize p53 through direct interaction with the 26S proteasome (see later). Recent reports have suggested that E1A can also up-regulate the p53-related protein, p73 (Steegenga et al., 1999; Zaika et al., 2001) . The report by Steegenga and colleagues suggested that E1A, when transfected into Hep3B cells, inhibited p73 transcriptional activity through binding to CBP/p300, whereas Zaika and colleagues suggested that the up-regulation of p73, in Figure 3 Stabilization of p53 by E1A. E1A stabilizes p53 by targeting dierent regulatory components important in p53 degradation. Binding of CBP/p300 and Rb to E1A has been implicated in p53 stabilization (Chiou and White, 1997; Querido et al., 1997) . E1A binding to Rb, through CR1 and CR2, promotes E2F-dependent transcription of p19 ARF (de Stanchina et al., 1998) . p14 ARF binds to Hdm2 and inhibits Hdm2 ubiquitin ligase activity directed towards p53 (Honda and Yasuda, 1999) . E1A binding to CBP/p300, through its N-terminus and CR1, might also inhibit the ability of Hdm2 to ubiquitylate p53, CBP/ p300 is implicated in Hdm2-dependent degradation of p53 (Grossmann et al., 1998) . The N-terminus of E1A also inhibits p53 degradation through interaction with 19S RC ATPases of the 26S proteasome (Turnell et al., 2000) . See text for more detailed appraisal Saos-2 cells, led to the activation of p73-responsive genes and induction of apoptosis. The apparent dierences between the two reports cannot be easily explained, as both examined E1A eects in p53-null cells, but presumably re¯ect cell-type speci®c dierences/aberrations in p73 signalling pathways. Neither report however, indicated whether E1A up-regulates p73 through protein stabilization, akin to p53, or through enhanced transcription of the p73 gene. This awaits clari®cation.
The requirement for p53 stabilization by E1A during viral infection remains obscure. Interestingly, in the context of CBP/p300, E1A can inhibit p53-dependent transcription of target genes through binding CBP/ p300 (Lill et al., 1997; Somasundaram and El-Diery, 1997) , though whether this re¯ects what happens in vivo during Ad infection or Ad-mediated transformation is unclear. Indeed, how p53 stability relates to post-translational modi®cation (e.g. phosphorylation or acetylation) and p53 complex formation with other proteins e.g. CBP/p300, remains to be resolved. Is this function of p53 early in Ad infection related speci®cally to transcription activation/repression of a subset of genes involved in viral replication or does p53 participate directly in the process by which E1A promotes host cell S phase entry?
Regulation of the 26S proteasome The 26S proteasome serves to degrade protein substrates targeted by polyubiquitin modi®cation (Ciechanover, 1998) and exists both as cytoplasmic and nuclear species. E1A, through its N-terminal region, can be found in complexes with both S4 and S8 ATPases of the 19S regulatory complex (RC) in both cellular compartments (Turnell et al., 2000) . E1A serves to inhibit ATPase activity associated with S4. The yeast orthologue of S4, Rpt2, has recently been identi®ed as the key ATPase involved in gating both entry of ubiquitin-tagged protein substrates into the 20S proteasomal core and exit of cleaved peptide products (KoÈ hler et al., 2001) . It seems likely therefore that E1A functions to inhibit entry of proteins into the proteolytic core. Indeed, the N-terminus of E1A can inhibit proteasomal-mediated degradation of p53 (Turnell et al., 2000) , through direct interaction with 19S RC ATPases. It could also inhibit peptide release from the 20S core, aecting the generation of peptides for antigen presentation. The signi®cance of E1A binding to S8 remains to be established. However, there is growing evidence linking protein stability and ubiquitylation to transcriptional control (Molinari et al., 1999; Hoppe et al., 2000) . S8 can function outside the proteasome, as a DNA helicase (Fraser et al., 1997) , and to stimulate transcription, in a liganddependent manner, through binding to nuclear hormone receptors (Lee et al., 1995; vom Baur et al., 1996) . It is tempting to speculate that E1A interaction with the proteasomal ATPases could also impinge directly on transcriptional control.
E1A not only aects protein degradative processes through direct interaction with the 26S proteasome, but it might also regulate the ubiquitin conjugation machinery (E2 enzymes) through interaction of CR2 with UBC9 (Hateboer et al., 1996) . UBC9, has recently been implicated in conjugation of the ubiquitin-like molecule SUMO-1 to protein substrates. The consequences of SUMOylation are far-reaching. SUMOylation, in contrast to ubiquitylation, does not necessarily target proteins for degradation. Dependent on the protein substrate, SUMOylation can enhance protein stability, alter protein localization, and impinge on signal transducing pathways that regulate stress responses and cell cycle progression (Muller et al., 2001 ). The precise consequences of the interaction between E1A and UBC9 however, are currently unknown.
Immune evasion and tumorigenicity E1A interferes with a number of pathways involved in immune regulation; evasion of T-cell immunity is a major determinant in Ad tumorigenicity (Bernards et al., 1983b) . It has been known for some time that the tumorigenic serotype, Ad12, and the non-tumorigenic serotype, Ad5, dierentially regulate the presentation of MHC class 1 antigens . It has been suggested that Ad tumorigenicity is due to the 20 amino acid spacer region present in Ad12 between CR2 and CR3, which is not present in the non-tumorigenic Ad serotypes (Jelinek et al., 1994; Telling and Williams, 1994) . Mutation of this region does reduce tumorigenicity, but does not abolish it. The N-terminus through CR2 was also shown to be required for Ad tumorigenicity. These regions have also been implicated in mediating the down-regulation of MHC class 1 molecules (Pereira et al., 1995) . Work from Robert Ricciardi and colleagues, has suggested that a major dierence between oncogenic and non-oncogenic serotypes resides in their ability to aect transcription mediated through the MHC class 1 enhancer sites R1 and R2 (Kushner et al., 1996) . Oncogenic serotypes repress transcription mediated through the class 1 enhancer by up-regulating COUP-TFII (Smirnov et al., 2001) , which binds to the R2 site, whilst concomitantly reducing the level of NF-kB binding to the R1 site by reducing the level of phosphorylation of the p50 subunit of NF-kB (Kushner and Ricciardi, 1999) . In contrast, non-oncogenic serotypes do not up-regulate COUP-TFII levels, and NF-kB binds to the R1 site with high anity. COUP-TFII represses transcription by recruiting HDAC-1 and N-CoR to the response element (Smirnov et al., 2000) . Oncogenic serotypes have also been shown to interfere with MHC class 1 presentation by down-regulating LMP2 and LMP7, components of the immune proteasome. Recent evidence suggests that E1A down-regulates LMP2 expression through direct binding to STAT-1 (Chatterjee- Kishore et al., 2000) . E1A disrupts STAT-1 interaction with IRF-1, thus preventing STAT-1/IRF-1 heterodimers from stimulating transcription from the ICS/GAS response element in the LMP2 promoter (Chatterjee-Kishore et al., 2000) . Oncogenic serotypes also down-regulate transporter proteins associated with antigen presentation, TAP1 and TAP2 (Rotem-Yehudar et al., 1994) . LMP2 and TAP1 are regulated by a bi-directional promoter that has an NF-kB response element (Prott and Blair, 1997) . It has been suggested that, akin to the MHC enhancer, E1A could reduce NF-kB binding to the promoter. However, many of these studies have been carried out in transformed cells or by DNA transfection and it is still not clear if any of these mechanisms lead to immune evasion in the normal host. Whether E1A impinges on antigen presentation through direct interaction with the 26S proteasome or the immune proteasome awaits further investigation.
Important riddles to solve
We are blissfully ignorant of the life cycle of human adenoviruses in the natural host and for one of the viruses discussed at length here, Ad12, we do not even know the target tissue. It is fair to assume that when the host is infected, the target cell will be dierentiated and initially will be receiving a very low infectious virus dose. This is a much more restrictive and hostile environment than the laboratory virus endures. There the tissue culture dish contains cells that are usually in cycle (most of the cell lines used are already defective for one or other of the pathways E1A has evolved to subvert) and there are no cells of the immune system ready to pounce. Infection of growth arrested normal human cells signi®cantly reduces Ad virus yield (Turnell et al., 1999) . Can we say we really understand the infection process when we have been restricted to studying the Ad life cycle in this way? However, we have to believe that these tissue culture studies have provided us with some of the secrets of these fascinating viruses. If, as has been proposed earlier, one of the major immediate early functions of the virus is to reprogramme host cell transcription then we propose that the proteins involved in remodelling chromatin will be high anity targets for E1A (this will be especially true when E1A levels are initially low). Naked DNA in the host nucleus is at great risk of being degraded and therefore chromatinization would seem a logical way for the virus genome to be retained. If this occurs, let's say, in a dierentiated upper respiratory tract epithelial cell, it seems very likely that E1A mobilizes and regulates elements of the host chromatin remodelling complexes not only to change host transcription but also to control the dierent phases of the virus life cycle. In terms of the deregulation of the host cell's transcriptional control, is E1A just acting as an inhibitor (transcription repression) and/or activator (transcription activation) of remodelling complexes or does E1A act more speci®-cally by mobilizing the remodelling complexes to de®ned targets? It has not escaped our notice that the binding sites for the acetylases (p300, CBP and p/CAF) reside at E1A's N-terminus, whilst repression (CtBP) complexes bind to the C-terminus. It is therefore possible that there may be molecular cross-talk between the two ends of E1A if individual E1A molecules bind more than one E1A binding protein at a time. It is surprising that we do not know if E1A really forms multicomponent complexes with more than one of its binding partners. Does E1A modify any aspect of antigen presentation and/or protect the cell from immune response modifying molecules such as the interferons? Any pathway that might alert the immune system or inhibit cell cycle progression into a pseudo-S phase would seem to us to be likely E1A targets in the natural host.
There are clearly well documented roles for E1A in the nucleus but there is very little data available on the role of cytoplasmic E1A. We believe that cytoplasmic E1A contributes signi®cantly to the overall disruption of cell biochemistry during infection and transformation. Targets are beginning to emerge like the proteasomal ATPases (Turnell et al., 2000) , PKA RIIa (Fax et al., 2001) and CtBP/BARS (Weigert et al., 1999) . Does E1A have a more general role as a nuclear import factor and is it interfering with signaling pathways via the Golgi system? Where in all of this does the post-translational modi®cation of E1A (phosphorylation (Tremblay et al., 1988; Dumont et al., 1989; Whalen et al., 1996) and acetylation ) feature? Are phosphorylation and acetylation the only post-translational modi®cations? Surprisingly, we have little idea of how the relatively short half-life of E1A is regulated, although it has been reported that the 289R E1A has a shorter half-life than 243R (Spindler and Berk, 1984) and that sequences in exon 2 also determine E1A half-life (Turnell et al., 2000) .
The alanine rich region between CR2 and CR3 in Ad12 E1A that is important for Ad oncogenesis (Williams et al., 1995) is contained within both the 235R and 266R Ad12 E1A's. In addition, unlike the 243R protein encoded by Ad2/5 12S mRNA, the Ad12 12S counterpart 235R E1A, also contains the Nterminal portion of CR3. Are these additional amino acids a binding site for another as yet unidenti®ed tumour suppressor protein in addition to TBP (Molloy et al., 1999) or do these sequences add to the Ad12 E1A structural constraints and modify protein binding elsewhere on E1A? Finally, we still have no idea what function(s) the Ad12 E1B 54K protein provides in its co-operation with E1A in adenovirus oncogenesis.
Adenovirus research over the past 40 years has provided us with a wealth of data on how many of the fundamental processes of life are regulated and has identi®ed several of the key players. No one could have predicted on reading the Trentin, Yabe and Taylor paper of 1962 ) that this would have had such far-reaching consequences. With the human genome project near completion, it is pertinent to ask if adenovirus research has any future. We contend that Ads subvert most, if not all, of the major signaling pathways and processes in the cell and that our understanding of how this is achieved is currently only rudimentary. We believe that research on viral proteins, allied to developments in the ®eld of proteomics, have a longterm future and that many more important discoveries lie ahead. If, on top of this, adenovirus anti-cancer therapy becomes part of the Oncologist's armoury in the next decade, this alone will have vindicated all of the billions spent on adenovirus research.
